Logo-ijbsm
Submitted: 28 Nov 2022
Accepted: 25 Mar 2023
ePublished: 29 May 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Int J Basic Sci Med. 2023;8: 36-41.
doi: 10.34172/ijbsm.2023.06
  Abstract View: 318
  PDF Download: 254

Original Article

The Effect of Bromelain Combined With Montelukast in Hospitalized COVID-19 Patients

Alireza Jahangirifard 1 ORCID logo, Kamal Fani 2 ORCID logo, Seyed Bashir Mirtajani 1* ORCID logo

1 Lung Transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Author: Seyed Bashir Mirtajani, Email: bashirmirtajani67@gmail.com

Abstract

Introduction: The activation of bradykinin B1 receptors on endothelial cells in the lung following inflammation is a major cause of the severity and mortality of COVID-19. It has already been shown that bromelain and montelukast as two anti-inflammatory agents can be effective in controlling this condition.

Methods: Patients with the novel coronavirus (COVID-19) referred to Masih Daneshvari hospital in Tehran were included in the study after providing full explanations and obtaining written consent. All 40 patients with moderate symptoms were randomly divided into the placebo (n=20) and intervention (n=20) groups. In the sample group, a dose of 200 mg oral bromelain was given to patients every 8 hours and one tablet of montelukast 10 mg 1 hour before or after dinner for 5 days. In the control group, placebo capsules were administered exactly at the above intervals. The results were evaluated using a t test and SPSS21 software.

Results: After treatment, the sample (bromelain and montelukast) group represented significant improvements in C-reactive protein (CRP), lactate dehydrogenase (LDH), and lymphocyte count (P<0.05), while the other factors did not have significant differences with the control group.

Conclusion: Bromelain and montelukast can improve the condition of hospitalized COVID-19 patients by the positive effect on oxygen saturation, lymphocytes, serum levels of CRP, and LDH.

Keywords: Bromelain, Montelukast, COVID-19, Inflammatory response, Clinical symptoms, Respiratory parameters, Immunological factors

Please cite this article as follows: Jahangirifard A, Fani K, Mirtajani SB. The effect of bromelain combined with montelukast in hospitalized COVID-19 patients. Int J Basic Sci Med. 2023;8(1):36-41. doi:10.34172/ijbsm.2023.06.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 319

Your browser does not support the canvas element.


PDF Download: 254

Your browser does not support the canvas element.